Search research articles
Contact Us
Filters
Showing results (101-110 of 148) with videos related to
Page
of 15
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 4, 2020
Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials
Marco Marcello, James W Denham, Angel Kennedy, et al.
Trials
|
September 18, 2012
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
Matthew R Sydes, Mahesh K B Parmar, Malcolm D Mason, et al.
European Urology
|
March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
Pasquale Rescigno, David Lorente, Diletta Bianchini, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 4, 2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial
James M Wilson, David P Dearnaley, Isabel Syndikus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
Susan Halabi, Akash Roy, Larysa Rydzewska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials
Lucia Kwak, Praful Ravi, John G Armstrong, et al.
The Lancet. Oncology
|
March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
David P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
The Lancet. Oncology
|
May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P Dearnaley, Matthew R Sydes, John D Graham, et al.
European Urology
|
July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
The New England Journal of Medicine
|
August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapy
Juanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 148) with videos related to
Sort By:
Page
of 15
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 4, 2020
Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials
Marco Marcello, James W Denham, Angel Kennedy, et al.
Trials
|
September 18, 2012
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
Matthew R Sydes, Mahesh K B Parmar, Malcolm D Mason, et al.
European Urology
|
March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
Pasquale Rescigno, David Lorente, Diletta Bianchini, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 4, 2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial
James M Wilson, David P Dearnaley, Isabel Syndikus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
Susan Halabi, Akash Roy, Larysa Rydzewska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials
Lucia Kwak, Praful Ravi, John G Armstrong, et al.
The Lancet. Oncology
|
March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
David P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
The Lancet. Oncology
|
May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P Dearnaley, Matthew R Sydes, John D Graham, et al.
European Urology
|
July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
The New England Journal of Medicine
|
August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapy
Juanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
Page
of 15